You are here

Article Text

Article menu

Download PDFPDF

Abstracts Accepted for Publication
Vasculitis
AB0591 Efficacy and safety profile of intravenous cyclophosphamide treatment in elderly patients with systemic vasculitis
Free
  1. S Shimoyama1,
  2. T Kurita1,
  3. S Fukaya2,
  4. M Kanda2,
  5. on behalf of Japanese Red Cross Kitami Hospital, Hokkaido P.W.F.A.C. Obihiro Kosei Hospital
  1. 1Internal medicine/ General medicine, Japanese Red Cross Kitami Hospital, Kitami
  2. 23rd Department of Internal medicine, Hokkaido P.W.F.A.C. Obihiro-Kosei General Hospital, Obihiro, Japan

Abstract

Background Intravenous cyclophosphamide is mainstay of remission induction and dose reduction of glucocorticoid in patients with systemic vasculitis. However, little evidence has yet shown the safety profile of intravenous cyclophosphamide, especially in elderly patients.

Objectives To evaluate efficacy and safety of patients diagnosed as systemic vasculitis and treated with intravenous cyclophosphamide.

Methods This retrospective study comprised the patients with active systemic vasculitis who were admitted to Kitami Red Cross Hospital and Obihiro-Kosei General Hospital from April 2009 to March 2016. These patients were treated with intravenous cyclophosphamide plus conventional therapy (IVCY group) or only with conventional therapy (glucocorticoid/azathioprine/tacrolimus and methotrexate) (conventional therapy group). The patients treated with oral cyclophosphamide or rituximab were excluded. Primary endpoint was defined as death or serious infections. Prognostic factors in IVCY group were analyzed by multivariate Cox regression methods.

Results This study comprised 90 patients with active systemic vasculitis (61 microscopic polyangiitis, 9 eosinophilic granulomatosis with polyangiitis, 10 granulomatosis with polyangiitis, and 10 polyarteritis nodosa). Fifty-one patients were over 70-year-old (26 patients in IVCY group). The mean observation period was 30.1 months. IVCY group had a trend for higher event-free survival rate as compared with conventional therapy group (p=0.19). IVCY group had significantly higher cumulative survival rate as well (p=0.04). Age (HR=1.07, 95% CI 1.01–1.14, p=0.03), five factor score (FFS, HR=3.39, 95% CI 1.36–8.44, p=0.01) and glucocorticoid dose at 24 weeks (GC24, HR=1.14, 95% CI 1.05–1.22, p=0.001) were identified as risk factors for events. In patients over 70-year-old, IVCY group had a trend for higher cumulative survival rate as well (p=0.07, Figure1). FFS (HR=3.30, 95% CI 1.19–9.15, p=0.02) and GC24 (HR=1.10, 95% CI 1.02–1.20, p=0.01) were identified as risk factors for events.

View this table:
Table 1.

Background of patients with IVCY group and conventional therapy group

Figure

Conclusions Intravenous cyclophosphamide treatment had acceptable safety profile even in elderly patients.

Disclosure of Interest None declared

https://doi.org/10.1136/annrheumdis-2017-eular.3338

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.